Portfolio Company News
2010
- 26 July 2010 - Momenta Pharmaceuticals Announces FDA Approval for First Generic Lovenox(R)
- 26 July 2010 - Carfilzomib Phase 2b Data Better Than Expected With 24% ORR. We Continue To Like Long-Term Nexavar Prospects Along With In
- 30 June 2010 - Celgene to Acquire Abraxis BioScience
- 25 June 2010 - Gilead to Buy CGI Pharmaceuticals for $120 Million
- 22 June 2010 - Pharmaxis Announces Results For Second Phase Iii Trial Of Bronchitol In Cystic Fibrosis
- 21 June 2010 - Affymax and Takeda Announce Phase 3 Trials Meet Primary Endpoints for Investigational Drug, Hematide(TM)/peginesatide, to Treat Anemia in Chronic Renal Failure With Some Differences Noted in Secondary Analyses
- 17 June 2010 - Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
- 16 June 2010 - Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
- 6 June 2010 - Cephalon Provides Clinical Update on Phase II Study of NUVIGIL as an Adjunctive Therapy in Adults with Schizophrenia
- 2 June 2010 - ProStrakan - Abstral PDUFA Date Update
- 2 June 2010 - Alexion Accelerates Plans to Launch Soliris(R) (Eculizumab) in Japan
- 1 June 2010 - Covidien Announces Definitive Agreement to Acquire ev3
- 1 June 2010 - FDA approves Amgen's Prolia for the treatment of postmenopausal women with osteoporosis
- 28 May 2010 - Amgen Granted EU Marketing Authorization for Prolia
- 26 May 2010 - Vertex Pharma Shares Up 9.72% After Announcing Positive Results
- 25 May 2010 - Genzyme Receives FDA Approval for Lumizyme for Pompe Disease
- 16 May 2010 - OSI is acquired for $4 billion
- 6 May 2010 - Incyte Reports First Quarter 2010 Financial Results – and describes positive top-line Phase II results for INCB28050 for rheumatoid arthritis
- 5 May 2010 - Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE Antibody
- 4 May 2010 - Pharmasset Announces Results of a 28-day Phase 2a Study with PSI-7977 for the Treatment of Chronic Hepatitis C Infection
- 4 April 2010 - Ardea Biosciences, Inc. Announces Completion of Public Offering of Common Stock
- 1 April 2010 - ProStrakan Receives Complete Response for Rectogesic from FDA
- 31 March 2010 - Ardea Biosciences Announces Positive Top-Line Results from a Phase 2b Study of RDEA594 Given as Monotherapy in the Treatment of Hyperuricemia in Gout Patients
- 29 March 2010 - Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
- 24 March 2010 - Genzyme Announces FDA Enforcement Action Regarding Allston Plant
- 11 March 2010 - Pharmaxis Completes Phase II clinical study with ASM8 in asthma patients
-
9 March 2010 – Micromet announces Proposed Public Offering of Common Stock
-
1 March 2010 - OSI Pharmaceuticals Confirms Receipt of Unsolicited Proposal From Astellas Pharma
-
23 February 2010 - Cephalon Exercises its Option to Acquire Ception Therapeutics
-
19 February 2010 - Basilea to regain full global rights to ceftobiprole
-
19 February 2010 – Basilea - European CHMP adopts negative opinion on ceftobiprole
- 19 February 2010 – Excellent results in a transformational year for Shire; core product sales up 25%
- 10 February 2010 - Genzyme - Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint
- 8 February 2010 - Amgen - Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases
- 3 February 2010 - Vertex Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis
- 28 January 2010 - Halozyme - Pharmasset Prices Underwritten Offering of Common Stock
- 20 January 2010 - Halozyme - Roche invests about 190 Mio Swiss Francs in infusion-free administration device with new Herceptin formulation
- 15 January 2010 - OSI Pharmaceuticals - FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
- 12 January 2010 - Pharmaxis to acquire Canadian company TOPIGEN Pharmaceuticals Inc
- 7 January 2010 - Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat
- 6 January 2010 - Phase II Clinical Trial of Gilead's Investigational Integrase-Based, Once-Daily, Fixed-Dose "Quad"Regimen Meets 24-Week Primary Objective
2009
- 16 December 2009 - OSI Pharmaceuticals - FDA Advisory Committee Recommends Against Approving Tarceva for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
- 15 December 2009 - Addex - Development of ADX10059 Ended for Long-term Use
- 15 December 2009 - Positive Phase IIb Topline Clinical Data for Celgene Oral Compound Apremilast (CC-10004) Reported for Patients with Moderate-to-Severe Psoriasis
- 14 December 2009 - Second Pivotal Phase III Study of Gilead's Darusentan for Resistant Hypertension Misses Primary Endpoints
- 7 December 2009 - Celgene to Acquire Gloucester Pharmaceuticals
- 7 December 2009 - Celgene - First Randomised Study Comparing All-Oral REVLIMID(R) Regimen Compared to Autologous Stem Cell Transplant Presented at ASH
- 4 December 2009 - Vertex Pharmaceuticals Announces Exercise of Option by Underwriters of its Public Offering of Common Stock
- 4 December 2009 - Santarus Receives FDA Approval for Immediate-Release Omeprazole Tablet with Dual Buffers
- 2 December 2009 - Pharmaxis Announces Sustained Benefit with Bronchitol in Phase 3 Cystic Fibrosis Trial
- 1 December 2009 - Santarus Announces FDA Approval of Schering-Plough HealthCare Products' ZEGERID OTC
- 1 December 2009 - Genzyme Begins Shipping Newly Produced Cerezyme from Allston Plant
- 24 November 2009 - Affymax Announces Close of Common Stock Offering and Exercise of Underwriters' Overallotment Option
- 24 November 2009 - Shire Submits Biologics License Application (BLA) for REPLAGAL® with the U.S. Food and Drug Administration (FDA)
- 16 November 2009 - Genzyme Receives Complete Response Letter on Lumizyme Application
- 16 November 2009 - Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer Did Not Meet Primary Endpoint
- 15 November 2009 - Addex ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial
- 13 November 2009 - Genzyme Issues Letters to U.S. Healthcare Providers
- 9 November 2009 - QIAGEN to Acquire SABiosciences
- 5 November 2009 - Micromet Buys Out MedImmune's Remaining Rights to Blinatumomab
- 4 November 2009 - FDA Grants Priority Review for Shire’s velaglucerase alfa for Type 1 Gaucher Disease
- 3 November 2009 - Pharmasset - INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
- 29 October 2009 - Sanofi Buys Rights to Experimental Micromet Drug
- 29 October 2009 - Pharmaxis Applies to Market Bronchitol for Cystic Fibrosis in Europe
- 27 October 2009 - Ligand to Acquire Metabasis for Cash and Contingent Value Rights
- 26 October 2009 - BioMarin Acquires Huxley Pharmaceuticals, Inc.
- 22 October 2009 - Halozyme Says Roche Doses First Patient in Phase 3 Herceptin
- 19 October 2009 - Prostrakan Shares Fall as FDA Seeks More Information on Fortesta
- 19 October 2009 - Amgen: FDA Issues Complete Response Letter To Denosumab in postmenopausal osteoporosis
- 12 October 2009 - Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
- 17 August 2009 - GlaxoSmithKline and Genmab Announce Results from a Study of Arzerra in Rituximab Refractory Follicular NHL
- 14 August 2009 - Genzyme Drug Rationed More in Europe in Shortage
- 13 August 2009 - Amgen Bone Drug Backed for Limited Use by FDA Panel
- 4 August 2009 - Micromet Closes $80.5 Million Public Offering of Common Stock
- 22 July 2009 - Onyx Surges, Nexavar Fights Breast Cancer in Study
- 9 July 2009 - Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
- 7 July 2009 - Amgen Rises on Denosumab Test of Cancer Harm to Bones
- 8 June 2009 - Micromet’s up 30% as Blinatumomab Achieves Primary Endpoint in Phase 2 Study
- 30 May 2009 - Data from OSI Pharma's Phase III ATLAS Study Show Tarceva in Combination
- 29 May 2009 - Genmab – FDA ODAC panel recommends Arzerra
- 28 May 2009 - Poniard Pharmaceuticals Announces Progression-Free Survival Data
- 8 May 2009 - Covidien to Buy Device-Maker VNUS Medical for $440 Million
- 7 May 2009 - GE Healthcare and Hansen Medical Announce Collaboration to Promote Use of Fluoroscopic Imaging Systems and Robotic Catheter System for Electrophysiology Procedures
- 4 May 2009 - Pharmaxis announes positive Phase III Cystic Fibrosis trial
- 31 March 2009 - Genzyme-GENZ and Bayer-BAYRY enter new strategic agreement
- 24 March 2009 - (BN) Ligand Announces Osteoporosis Drug Fablyn Approved in Europe
- 12 March 2009 - Micromet, Inc. To Regain Rights to Blinatumomab in North America
- 12 March 2009 - Gilead Agrees to Buy CV Therapeutics for $1.4 Billion
- 26 February 2009 - European Authorities Approve Larger-Scale Production of Genzyme's Myozyme
- 12 February 2009 - Results of first interim efficacy analysis for Biomarin's Riquent PIII
- 2 February 2009 - Ligand Announces Phase IIb Results With DARA
- 16 January 2009 - Pfizer’s Bone-Drug Fablyn Fails to Win U.S. Approval
- 13 January 2009 - Santarus announces complete response letter from FDA on Schering-Plough's new drug application for OTC ZEGERID
Click here for IBT Portfolio Company News 2005 - 2008